Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2
| | | |

Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2

On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…

Cocrystal Pharma’s SARS-CoV-2 protease inhibitors ddemonstrated pan-viral activity against human common Coronaviruses, Noroviruses, Rhinoviruses and Enteroviruses
| | | |

Cocrystal Pharma’s SARS-CoV-2 protease inhibitors ddemonstrated pan-viral activity against human common Coronaviruses, Noroviruses, Rhinoviruses and Enteroviruses

On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…